Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors

Brief summary public domain (ClinicalTrials.gov)

This is the first clinical experience in Japan with GSK1120212, a novel MEK inhibitor. This study is designed to identify recommended doses and regimens in Japanese subjects for the future development of GSK1120212.

Detailed description public domain (ClinicalTrials.gov)

GSK1120212 has demonstrated anti-proliferative activity against a broad range of tumors cell lines and xenograft models. To date, MEK inhibitors have demonstrated evidence of both pharmacodynamic and clinical activity in early trials. This is the first clinical experience in Japan with GSK1120212, a novel MEK inhibitor. This study is designed to identify recommended doses and regimens in Japanese subjects for the future development of GSK1120212. This study will be conducted in subject with solid tumors, and GSK1120212 single agent treatment to assess safety, tolerability, PK and efficacy (Part 1) and combination treatment with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which gemcitabine has been approved in 4-week schedule to assess safety, tolerability, PK and efficacy(Part 2) will be conducted in the same protocol.

Intervention public domain (ClinicalTrials.gov)

Drug: GSK1120212. Part1 and Part2

Intervention public domain (ClinicalTrials.gov)

Drug: Gemcitabine. Part2

Arm public domain (ClinicalTrials.gov)

GSK1120212 (experimental): Part 1-Dose escalation will be conducted to assess PK after single dosing and safety, tolerability, PK and efficacy of GSK1120212 in Japanese subjects with solid tumors using a continuous daily dosing schedule.

Arm public domain (ClinicalTrials.gov)

GSK1120212+Gemcitabine (experimental): Part 2-Further evaluate the safety, tolerability, PK, and efficacy of GSK1120212 in combination with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which 4-week schedule of gemcitabine has been approved using the recommended dose from Part 1 (single agent).

Primary outcome public domain (ClinicalTrials.gov)

Number of participants with adverse events as a measure of safety and tolerability. Time frame: Until a subject has a Dose Limiting Toxicity, withdraws from the study or dies.

Secondary outcome public domain (ClinicalTrials.gov)

To assess pharmacokinetics (PK) parameter (AUC, Cmax, tmax etc.) values for GSK1120212. Time frame: Cycle0, Cycle1 Day1,8,15,22, Cycle2 Day1 in Part 1.

Secondary outcome public domain (ClinicalTrials.gov)

To assess pharmacokinetics (PK) parameter (AUC, Cmax, tmax, etc.) values for GSK1120212 and Gemcitabine. Time frame: Cycle1 Day15 in Part2.

Secondary outcome public domain (ClinicalTrials.gov)

Number of participants with the indicated tumor response defined by RECIST v1.1. Time frame: Every eight weeks during the study.

Secondary outcome public domain (ClinicalTrials.gov)

Serum level of cyctokines. Time frame: Cycle1 Day15 in Part1 and Part2.

Secondary outcome public domain (ClinicalTrials.gov)

Tissue level of expression of the indicated protein including pERK and Ki67 if possible. Time frame: Cycle1 Day15 in Part1 and Part2.

Secondary outcome public domain (ClinicalTrials.gov)

Tissue level of gene mutation including BRAF and KRAS if possible. Time frame: Cycle1 Day15 in Part1 and Part2.

Eligibility public domain (ClinicalTrials.gov)

Inclusion Criteria: Correspond Part 1 (Single agent) and Part 2 (Combination) * Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form * Age 20 years old or older at consent given * Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels * Negative for hepatitis B surface (HBs) antigen, hepatitis virus Bc (HBc) antibody, and HBs antibody. HBs antigen-negative subjects who test positive for both HBc antibody and HBs antibody or either of them may be eligible when their HBV DNA quantification result is negative * Negative HCV antibody test * Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from the time of the first dose of GSK1120212 until 16 weeks after the last dose of GSK1120212 * A female subject is eligible to participate if she is of;Non-childbearing potential females or female subjects with child-bearing potential must agree to use contraception until four weeks after the last dose of GSK1120212 to sufficiently minimize the risk of pregnancy at that point Part 1 -Dose escalation single agent part * Histologically or cytologically confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no approved or curative therapy. Subjects with primary brain tumor are excluded * Adequate organ system functions as defined below; Absolute neutrophil count≥1,200/uL Hemoglobin≥9g/dL Platelets≥75,000/uL PT/INR and APTT≤1.3xULN Albumin≥2.5g/dL Total bilirubin≤1.5xULN AST and ALT≤2.5xULN Creatinine≤ULN OR Calculated creatinine clearance≥50mL/min OR 24-hour urine creatinine clearance≥50mL/min Left ventricular Ejection fraction≥LLN by ECHO or MUGA Part 2 -Combination part * Tumor type criteria;Histologically or cytologically confirmed diagnosis of solid tumor malignancy. Eligible are the cancers for which gemcitabine has been approved in 4-week schedule;1,000mg/m2 weekly for 3weeks followed by 1 week rest at the 4th week, including non-small cell lung cancer, pancreatic cancer, biliary cancer, and urothelial cancer, to which gemcitabine monotherapy is considered to be appropriate * Adequate organ system functions as defined below; Absolute neutrophil count≥1,500/uL …

Enrollment public domain (ClinicalTrials.gov)

Enrollment: 19 participants (actual).